Clinical Trials Logo

Supratentorial Glioblastoma clinical trials

View clinical trials related to Supratentorial Glioblastoma.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05052957 Recruiting - Clinical trials for Glioblastoma Multiforme

hSTAR GBM (Hematopoetic Stem Cell (HPC) Rescue for GBM)

hSTAR GBM
Start date: January 20, 2023
Phase: Phase 2
Study type: Interventional

This phase II trial studies the effect of P140K MGMT hematopoietic stem cells, O6-benzylguanine, temozolomide, and carmustine in treating participants with supratentorial glioblastoma or gliosarcoma who have recently had surgery to remove most or all of the brain tumor (resected). Chemotherapy drugs, such as 6-benzylguanine, temozolomide, and carmustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing. Placing P140K MGMT, a gene that has been created in the laboratory into bone marrow making the bone more resistant to chemotherapy, allowing intra-patient dose escalation which kills more tumor cells while allowing bone marrow to survive.